Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 19:3:64-67.
doi: 10.1016/j.ijchv.2014.03.007. eCollection 2014 Jun.

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

Muhammad Tariq Shakoor  1   2 , Samia Ayub  1   2 , Sajid Dhakam  2
Affiliations

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

Muhammad Tariq Shakoor et al. Int J Cardiol Heart Vessel. .

Abstract

Background: Abciximab reduces major adverse cardiac events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab bolus during PCI plus abciximab infusion for 12-18 h post pPCI. Intracoronary (IC) abciximab bolus administration results in high local drug concentrations and hence it should have higher antiplatelet effect. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in ACS patients during pPCI.

Methods: We compared the clinical outcomes between the IC (n = 56) and standard protocol (n = 170) group of patients. Primary endpoints included bleeding/vascular/ischemic complications and MACE.

Results: The two groups were similar with respect to baseline characteristics. IC abciximab bolus only reduced bleeding complications, with no moderate bleed versus 7.2% in standard protocol group (p value 0.04). Ischemic/vascular complications had statistically insignificant difference between the two groups.

Conclusion: We found no significant difference between IC abciximab bolus only and standard abciximab therapy in terms of ischemic/vascular complications and MACE. But there was higher risk of moderate bleed in standard therapy group. The IC bolus route of abciximab may be superior to the intravenous route. Prospective randomized trials are warranted to validate these findings.

Keywords: Abciximab; Acute coronary syndrome; Primary percutaneous coronary intervention.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. Circulation. 2004;110:588–636. - PubMed
    1. Lerman A., Holmes D.R., Herrmann J., Gersh B.J. Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? Eur Heart J. 2007;28:788–797. - PubMed
    1. Thiele H., Schindler K., Friedenberger J., Eitel I., Fürnau G., Grebe E. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49–57. - PubMed
    1. Topol E.J., Lincoff A.M., Kereiakes D.J., Kleiman N.S., Cohen E.A., Ferguson J.J. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6. - PubMed
    1. EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92. - PubMed

LinkOut - more resources